2014.PE.HSA

基于多柔比星的化疗对右心房肿块和心包积液狗的回顾性评估

A retrospective evaluation of doxorubicin-based chemotherapy for dogs with right atrial masses and pericardial effusion

摘要

Objective: To report the outcome of doxorubicin-based chemotherapy as the sole treatment for dogs with echocardiographically identified right atrial masses and pericardial effusion.

目的：报告以多柔比星为基础的化疗作为超声心动图识别为右心房肿块和心包积液的狗的唯一治疗方法的结果。

Methods: A retrospective study of case records of dogs with right atrial masses treated with doxorubicin. Dogs were excluded from the study if they had any type of surgery performed such as pericardiectomy or right atrial mass resection, or if their chemotherapy protocol did not include doxorubicin. The data collected included signalment, history, physical examination findings, diagnostic test results and long-term survival.

方法：对接受多柔比星治疗的右心房肿块狗的病例记录进行回顾性研究。如果狗进行了任何类型的手术，例如心包切除术或右心房肿块切除术，或者它们的化疗方案不包括多柔比星，则它们被排除在研究之外。收集的数据包括信号、病史、体格检查结果、诊断测试结果和长期生存率。

Results: Dogs with right atrial masses and pericardial effusion that received doxorubicin-based chemotherapy alone had a median survival of 139 · 5 days (range 2 to 302 days). Chemotherapy side effects were frequent but mild.

结果：仅接受多柔比星化疗的右心房肿块和心包积液的狗的中位生存期为 139.5 天（范围 2 到 302 天）。化疗副作用频繁但轻微。

Clinical significance: Doxorubicin-based chemotherapy alone appears to be a viable treatment option for dogs with echocardiographically identified right atrial masses and pericardial effusion.

临床意义：单独使用基于多柔比星的化疗似乎是超声心动图识别为右心房肿块和心包积液的狗的可行治疗选择。